MAPS in Silicon Valley: MDMA Biomarker Analysis at Stanford

Dean S. Carson from Stanford University details ongoing clinical research evaluating the use of MDMA in conjunction with psychotherapy for the treatment of social anxiety in autistic adults. The study investigates physiological biomarkers including oxytocin and vasopressin to assess treatment efficacy and provide insights into the underlying mechanisms of change. This research reflects a shift toward systems-level approaches in psychiatric treatment. Funding represents a significant hurdle for this work as government support has historically focused on basic science or drugs with clear intellectual property potential. Private funding is essential to advance this clinical research and eventually encourage broader institutional support for similar investigations.